New drug candidate targets advanced colorectal cancer in early trial

NCT ID NCT06464692

Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an investigational drug called telisotuzumab adizutecan in about 30 Chinese adults with advanced colorectal cancer that cannot be removed by surgery. The main goals are to check safety and how the drug moves through the body. Participants receive different doses of the drug through an IV, and researchers will monitor side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telisotuzumab adizutecan (ABBV-400)
What this could lead to: If it works, this could point toward a new treatment option for advanced colorectal cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early, small phase 1 study focused on safety and dosing, not on proving effectiveness. The drug may cause serious side effects like lung inflammation or low blood cell counts, and it may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Show contact details

Locations

Beijing Cancer Hospital /ID# 263297

Beijing, Beijing Municipality, 100142, China
First Affiliated Hospital of China Medical University /ID# 263338

Shenyang, Liaoning, 110001, China
Harbin Medical University Cancer Hospital /ID# 263049

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital /ID# 263172

Zhengzhou, Henan, 450008, China
Hubei Cancer Hospital /ID# 263248

Wuhan, Hubei, 430079, China
The First Affiliated Hospital of Nanchang University /ID# 263193

Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital of College of Medicine - Zhejiang University /ID# 263094

Hangzhou, Zhejiang, 310000, China
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 263309

Guangzhou, Guangdong, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.